drugset / Trial / NCT03660761
Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors
NaSingle-groupOpen-labelTreatment
Summary
The patient was given a daily dose of apatinib 500mg (or based on weight). Individualized chemotherapy regimens were given based on molecular expression and prior chemotherapy.
Timeline
- Start
- 2016-03-03
- Primary completion
- 2017-01-03
- Completion
- 2018-01-06
Publications
- Results Kasper H. [The supplying of vitamin A after pancreatectomy]. Med Welt. 1968 Jan 20;3:178-80. No abstract available. German.
- Results Potapova TV, Sharovskaia IuIu, Kovalev SA, Mittel'man LA, Chailakhian LM. [Effect of the ion composition of the surrounding medium on membrane potentials of L cells]. Tsitologiia. 1972 Nov;14(11):1335-41. No abstract available. Russian.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 425 mg | — |
| Subject | Rivoceranib | Small molecule | 500 mg | — |
| Subject | Temozolomide | Small molecule | 100 mg/m2 | — |
Indications
No indication recorded.